S&P/ASX 200 Index (ASX: XJO) shares are 0.5% lower at 8,706.8 points on Tuesday.
With earnings season over, brokers have updated their ratings and 12-month price targets on scores of ASX 200 shares.
Here are three with strong upside potential.
Image source: Getty Images
Life360 Inc (ASX: 360)
The Life360 share price is $20.88, up 6.9% today.
Over the past month, this ASX 200 tech share has fallen 15%.
Bell Potter renewed its buy rating on Life360 shares but shaved its price target down from $35 to $34.
This suggests a potential 62% upside ahead.
Analyst Chris Savage said:
The 2Q2026 key metrics of MAU growth, paying circle growth and adjusted EBITDA were all ahead of our forecasts…
The 2026 guidance for MAU growth, consolidated revenue and adjusted EBITDA were all unchanged…
We retain our BUY recommendation and note we expect the buyback to be more active this quarter after only modestly commencing last quarter.
Pro Medicus Ltd (ASX: PME)
The Pro Medicus share price is $167, up 1% today and down 43% over 12 months.
Pro Medicus shares began rebounding in February, ahead of the broader sector, but it's been a topsy-turvy recovery.
The ASX 200 healthcare share almost doubled in value between late February and early July, then fell on profit-taking.
The Pro Medicus share price is up 5% since the broader sector pivoted on 3 June.
Morgans has an accumulate rating with a 12-month target of $230 on Pro Medicus shares.
This implies a potential 38% upside ahead.
The broker said:
FY26 confirms PME is executing at an even higher level than the market gave it credit for.
EBIT margin of 74.9% and constant currency EBIT growth of 30.6% both beat expectations comfortably, with the FX-driven softness in headline revenue a currency story, not a demand or execution one.
Momentum remains broad-based, implementations are ahead of schedule, renewals are a clean sweep, and the pipeline is opening up in new segments rather than just deepening in existing ones.
Looking ahead, FY27 is shaping as a genuine standout year.
Ramelius Resources Ltd (ASX: RMS)
The Ramelius Resources share price is $3.66, down 2.5% today.
Over the past month, this ASX 200 gold share has fallen 0.4%.
Morgans has a buy rating on Ramelius Resources shares with a $4.74 target.
This implies a potential 30% upside ahead.
The broker said:
RMS is expected to release FY27 guidance and an updated outlook to FY30 in Sep-26, following execution of the EPC contract for the Mt Magnet mill expansion, providing greater clarity on project costs and timing.
